Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 21:25:100663.
doi: 10.1016/j.ymgmr.2020.100663. eCollection 2020 Dec.

Diffuse large B-cell non-Hodgkin's lymphoma in Gaucher disease

Grant Bonesteele  1 , J Jay Gargus  1   2 , Emily Curtin  1 , Mabel Tang  1 , Barry Rosenbloom  3 , Virginia Kimonis  1
Affiliations

Diffuse large B-cell non-Hodgkin's lymphoma in Gaucher disease

Grant Bonesteele et al. Mol Genet Metab Rep. .

Abstract

Gaucher disease type 1 (GD1) is the most common lysosomal storage disease and affects nearly 1 in 40,000 live births. In addition, it is the most common genetic disorder in the Ashkenazi Jewish population with phenotypic variation presenting in early childhood to asymptomatic nonagenarians. There have been a number of studies showing an increased risk of certain malignancies in patients, especially non- Hodgkin's lymphoma (NHL) and multiple myeloma. We describe a 66-year-old Ashkenazi Jewish male with GD1 who was first started on enzyme replacement therapy (ERT) with imiglucerase for GD1 at age 57 years, followed a year later by the diagnosis of diffuse large b-cell non-Hodgkin's lymphoma (DLBCL). He was treated with R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, plus the monoclonal antibody rituximab), however relapsed and developed myelodysplasia necessitating an allo-stem-cell transplantation but succumbed to severe graft vs. host disease. In addition, we also describe a 38-year-old Ashkenazi Jewish male with GD1 who was diagnosed with DLBCL at age 22 years with Gaucher disease diagnosed on pre-treatment bone marrow biopsy which was confirmed by enzyme assay and genotyping. At age 24 years, he was started on ERT with imiglucerase and at age 35 years, he switched to eliglustat. He has remained in remission from the lymphoma. A meta-analysis of the literature will be elaborated upon and we will discuss the relationship of GD1 to NHL and discuss more recent information regarding lyso-GL1 and the development of NHL and multiple myeloma.

Keywords: B-cell lymphoma; GBA1; Imiglucerase; Non-Hodgkin's lymphoma; Thrombocytopenia; lysoGL-1.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Case report # 1. High-grade B-cell lymphoma pre-chemotherapy and pre-ERT in the neck (A), right forearm (B) and regression of the lesion post chemotherapy and post-ERT (C).
See this image and copyright information in PMC

References

    1. Online Mendelian Inheritance in Man, OMIM®. Johns Hopkins University; Baltimore, MD: 2020. https://www.omim.org/entry/230800# MIM Number: 230800. (Accessed September 10, 2020)
    1. Grabowski G.A., Dinur T., Osiecki K.M., Kruse J.R., Legler G., Gatt S. Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine. Am. J. Hum. Genet. 1985;37:499–510. - PMC - PubMed
    1. Brady R.O., Kanfer J.N., Shapiro D. Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem. Biophys. Res. Commun. 1965;18:221–225. doi: 10.1016/0006-291X(65)90743-6. - DOI - PubMed
    1. Jmoudiak M., Futerman A.H. Gaucher disease: pathological mechanisms and modern management. Br. J. Haematol. 2005;129:178–188. doi: 10.1111/j.1365-2141.2004.05351.x. - DOI - PubMed
    1. Grabowski G.A. Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet. 2008;372:1263–1271. doi: 10.1016/S0140-6736(08)61522-6. - DOI - PubMed